Paligenosis defines a tightly controlled program through which terminally differentiated cells re‑enter the cell cycle and ...

Across the immunity cycle, NPs can co-deliver tumor antigens and adjuvants to DCs, enhance major histocompatibility complex class I (MHC-I)-mediated cross-presentation, and promote cytotoxic T ...

Appointments enhance commercialization readiness as Zentalis advances registrational program for azenosertib in Cyclin-E1 positive ...

Cancer immunotherapy works by mobilizing the body's own immune system to recognize and destroy malignant cells.

QD 5:2 selected as azenosertib monotherapy pivotal study dose based on favorable benefit-risk profile in DENALI Part 2a, supporting ...

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company", 6990.HK) announced today that the results of the Phase III clinical study OptiTROP-Lung05, evaluating the company's trophoblast ...

In an all-comer PROC population, across multiple dose cohorts, manageable safety profile of the combination was observed with low frequency of high-grade adverse eventsActivity of the combined regimen ...

Citius Oncology, Inc. ("Citius Oncology") , an oncology?focused biopharmaceutical company and majority?owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") , today announced that ...

Detailed price information for Zentalis Pharmaceuticals Inc (ZNTL-Q) from The Globe and Mail including charting and trades.

Bernstein 42nd Annual Strategic Decisions Conference May 28, 2026 10:00 AM EDTCompany ParticipantsStéphane Bancel - CEO ...

Anyone who has ever had a mosquito bite knows the paradox: scratching feels good for a second, then the itch roars back worse ...

Outcomes for patients with high-risk large B-cell lymphoma (LBCL), defined by an International Prognostic Index (IPI) score ...